Education
About Us
Working with TipRanks
Follow Us
Simulations Plus (SLP)
NASDAQ:SLP
SLP Stock Chart & Stats
$18.76
-$4.39(-14.45%)
At close: 4:00 PM EST
$18.76
-$4.39(-14.45%)
Day’s Range― - ―
52-Week Range$12.39 - $37.67
Previous CloseN/A
Volume738.72K
Average Volume (3M)358.74K
Market Cap
$377.91M
Enterprise Value$253.61M
Total Cash (Recent Filing)$28.45M
Total Debt (Recent Filing)$719.00K
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Jan 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding20,144,564
10 Day Avg. Volume225,720
30 Day Avg. Volume358,741
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.28
Price to Sales (P/S)3.60
P/FCF Ratio16.36
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue3.16
Enterprise Value/Gross Profit5.87
Enterprise Value/Ebitda18.45
Forecast
1Y Price Target
$20.50Price Target Upside9.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.98
Revenue Forecast (FY)$80.32M
Bulls Say, Bears Say
Bulls Say
AI And Technology IntegrationThe bio-pharma industry needs AI and technologies to increase the odds of R&D success, and SLP's vision is generally aligned with the needs of its bio-pharma customers to bring effective therapies to market in a more rapid manner.
Market RecoveryThere are signs of stabilization in the market, with some pockets of recovery in the bio-pharma sector.
Software Segment GrowthRecent investments into cloud deployment and AI-enabled products are expected to drive continued strength in the Software segment, appealing to customers seeking next-gen solutions.
Bears Say
Customer Spending SlowdownBiopharma customer spending slowdown tied to macro concerns about geopolitical uncertainties, tariffs, and drug pricing have resulted in lighter-than-expected service revenues for SLP.
Revenue Growth ChallengesRevenue growth is still lagging, with SLP delivering -6.5% y/y revenue growth in F4Q:25 and another decline expected in F1Q:26.
Service Revenue DeclineServices revenues declined by 3% due to macroeconomic uncertainties, affecting the overall performance of the company.
Simulations Plus News
SLP FAQ
What was Simulations Plus’s price range in the past 12 months?
Simulations Plus lowest stock price was $12.39 and its highest was $37.66 in the past 12 months.
What is Simulations Plus’s market cap?
Simulations Plus’s market cap is $377.91M.
When is Simulations Plus’s upcoming earnings report date?
Simulations Plus’s upcoming earnings report date is Jan 08, 2026 which is in 10 days.
How were Simulations Plus’s earnings last quarter?
Simulations Plus released its earnings results on Oct 22, 2025. The company reported $0.1 earnings per share for the quarter, missing the consensus estimate of $0.194 by -$0.094.
Is Simulations Plus overvalued?
According to Wall Street analysts Simulations Plus’s price is currently Undervalued.
Does Simulations Plus pay dividends?
Simulations Plus pays a Quarterly dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Simulations Plus dividends here
What is Simulations Plus’s EPS estimate?
Simulations Plus’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Simulations Plus have?
Simulations Plus has 20,144,564 shares outstanding.
What happened to Simulations Plus’s price movement after its last earnings report?
Simulations Plus reported an EPS of $0.1 in its last earnings report, missing expectations of $0.194. Following the earnings report the stock price went down -2.213%.
Which hedge fund is a major shareholder of Simulations Plus?
Currently, no hedge funds are holding shares in SLP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Simulations Plus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.50 (9.28% Upside)
$20.50 (9.28% Upside)
Blogger Sentiment
Bullish
SLP Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 236.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.81%
12-Months-Change
Fundamentals
Return on Equity
-42.13%
Trailing 12-Months
Asset Growth
-36.46%
Trailing 12-Months
Company Description
Simulations Plus
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
SLP Stock 12 Month Forecast
Average Price Target
$20.50
▲(9.28% Upside)
Technical Analysis
Ownership Overview
17.28% Insiders
15.26% Mutual Funds
24.47% Other Institutional Investors
33.24% Public Companies and
Individual Investors